Friday, July 10, 2026

pharma · Influenza, Human · Influenza

Seqirus USA

Seqirus (Australia) Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Influenza, Human, Influenza, Influenza Virus. NovaPharmaNews links 9 clinical program(s), 11 drug profile(s),

Summit, USA HQ
8 Employees
TGA registrant Type
Company details
Status
Public
HQ
Summit, USA
Employees
8
Programs
9
Drugs
19
Patents
0
Clinical program

CSL Limited Influenza Vaccine

Approved · mab · Influenza

CSL Limited Influenza Vaccine for Influenza is a Approved program (mab) at Seqirus (Australia) Pty Ltd with 1 ClinicalTrials.gov record(s).

Internal code CSLCT-USF-06-28

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Seqirus (Australia) Pty Ltd
Phase
Approved
Modality
mab
Indication
Influenza
Status
completed
Trials
1